XNAS · GRI
-0.56% · -$0.0100 · Vol 43.0K
Market closed · last close 4:00 PM ET · price as of 16:24:38 ET
GRI Bio, Inc. Common Stock

GRI Bio, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$1.76
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is GRI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for GRI are being assembled.
About GRI Bio, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
5
Country
US

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.80
Day high
$1.86
Day low
$1.76
Previous close
$1.77
52W high
$2.32
-24.14% from high
52W low
$1.76
0% of range
Market cap
$3.1M
EPS
$-10.0000
Shares out
1.8M
Volume
43K
VWAP
$1.79
Price history computed in-house
1W
-3.56%
1M
-22.81%
SMA 50 $1.97 · below
SMA 200 $1.97 · below
52W position 0%
Veridion warehouse edge

Warehouse intelligence for GRI.

Veridion Score
43
0: 941: 482: 343: 104: 755: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

GRI insider activity

GRI Bio, Inc. Common Stock

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for GRI.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

GRI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GRI in this window.
Lobbying spend

GRI lobbying filings, year to date.

Registered lobbying filings matched to GRI Bio, Inc. Common Stock.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GRI in this window.
Latest news · GRI
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for GRI.
Options
Sovereign unlock shows live options positioning for GRI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.